Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02393937 · ClinicalTrials.gov registry record · Phase 3
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
A Phase 3 study of Papulopustular Rosacea and Erythematotelangiectatic Rosacea, sponsored by bioRASI.
- Completed
- Registry status
- Phase 3
- Development phase
- 963
- Enrollment target
- 20
- Study locations
NCT02393937: Completed Phase 3 study of Papulopustular Rosacea and Erythematotelangiectatic Rosacea, sponsored by bioRASI.
NCT02393937 is a Phase 3 study of Papulopustular Rosacea and Erythematotelangiectatic Rosacea that has completed, run by bioRASI. The registered enrollment target is 963 participants, above the 192-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target (402% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02393937, a Phase 3 study of Papulopustular Rosacea and Erythematotelangiectatic Rosacea, has completed, sponsored by bioRASI.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 963 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy of two Metronidazole Gels 1%, in the treatment of Rosacea.
Conditions Studied
Interventions
- DRUG Reference: Metronidazole Gel 1%
- DRUG Test: Metronidazole Gel 1%
- DRUG Placebo Gel
Study Locations (20)
Florida
- - Boca Raton
- - Clearwater
- - Miami
- - Miami
- - Miramar
- - Ocala
- - Tampa
California
- - Los Angeles
- - San Diego
North Carolina
- - High Point
- - Raleigh
Kentucky
- - Lexington
Massachusetts
- - Watertown
Nevada
- - Las Vegas
New York
- - New York
Ohio
- - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 963 participants |
| Start Date | 2015-02 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
What the finished NCT02393937 record still lists
NCT02393937 is an interventional study that assigns participants to a tested intervention. The registered 963 participants enrollment target is mid-sized for trials with a published cap, above the 192-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target (402% higher).
The record links to 2 conditions, with Papulopustular Rosacea appearing as the primary indexed condition, and to 3 interventions - of which Reference: Metronidazole Gel 1% is the first listed.
NCT02393937 names 20 study sites across 12 states, led by Florida, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02393937 about?
NCT02393937 is a clinical study titled "A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea". The purpose of this study is to compare the efficacy of two Metronidazole Gels 1%, in the treatment of Rosacea.
What is the current status of trial NCT02393937?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 963 participants. The study started on 2015-02. Estimated completion is 2015-10.
What conditions does trial NCT02393937 study?
This clinical trial studies the following conditions: Papulopustular Rosacea, Erythematotelangiectatic Rosacea.
What interventions are being tested in trial NCT02393937?
The interventions under investigation include: Reference: Metronidazole Gel 1% (DRUG), Test: Metronidazole Gel 1% (DRUG), Placebo Gel (DRUG).
Who is sponsoring clinical trial NCT02393937?
This trial is sponsored by bioRASI, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02393937 being conducted?
This trial has 20 study locations across California, Florida, Kentucky, Massachusetts, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papulopustular Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02393937's enrollment target sits among peer trials
963 1st of 11 higher than 11 of 11 other Papulopustular Rosacea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Papulopustular Rosacea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
COMPLETED · Phase 3
-
Phase 3 Papulopustular Rosacea Study
COMPLETED · Phase 3
-
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
COMPLETED · Phase 3
-
Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
RECRUITING · Phase 2
-
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
COMPLETED · Phase 1
-
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04726241 · 960 participants · Phase 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- NCT05142384 · 960 participants · NA
ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start
- NCT05178498 · 960 participants
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
- NCT05946629 · 960 participants · NA
SELUTION 4 De Novo Small Vessel IDE Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia